The effect of vitamin B-6 intervention to plasma homocysteine concentration, inflammatory responses and lipid peroxidation in metabolic syndrome

• Main Authors: Pin-Chieh, 陳品潔
• Other Authors: 黃怡嘉
• Format: Others
• Language: zh-TW
• Published: 2009
• Online Access: http://ndltd.ncl.edu.tw/handle/69876387857640292504

碩士 === 中山醫學大學 === 營養學研究所 === 97 === Metabolic syndrome has been recognized as abnormal lipid and pro-inflam¬matory status. It has been reported that vitamin B-6 could decrease plasma homocysteine concentration, inflammatory response, and lipid peroxidation. The purpose of this study was to investigate whether vitamin B-6 supplement could increase plasma pyridoxal 5’-phosphate (PLP) concentration and further decrease plasma homocyste¬ine concentration, inflammatory responses, and lipid peroxidation in sub¬jects with metabolic syndrome. Fifty subjects were recruited from the Divi¬sion of Metabolism, Chung Shan Medical University Hospital, Tai¬chung and were diagnosed as having metabolic syndrome according to the criteria of Bureau of Health Promotion, Department of Healthy, Tai¬wan, ROC. Subjects were randomly divided into the placebo group (n=24) and the vitamin B-6 group (100 mg/d vitamin B-6) (n=26). At week of 0, 4, 8, and 12, weight and height were measured. Fasting blood sample was ob¬tained to analyze hematological parameters and plasma vitamin B-6 status (PLP; 4-pyridoxic acid, 4-PA). Indicators of inflammatory responses (high sensitivity C-reactive protein; interleukin-6, IL-6, and fibrinogen) and lipid peroxidation (thiobarbituric acid reactive substances, TBARS; oxidized low-density lipoprotein, ox-LDL) were also measured. Results showed that 12 weeks of vitamin B-6 supplementation did not decrease plasma homocysteine concentration. However, IL-6 was significantly decreased by 0.001 pg/mL (= -0.001, p < 0.05) and ox-LDL was decreased by 0.020 mU/L (= -0.020, p < 0.01). Although vitamin B-6 intervention could not decrease fasting plasma homocysteine concentration, it significantly decreased the inflammatory response (IL-6) and lipid peroxidation (ox-LDL) in subjects with metabolic syndrome.